TY  - GEN
AU  - Subbiah,Vivek
AU  - Slopis,John
AU  - Hong,David S
AU  - Ketonen,Leena M
AU  - Hamilton,Jackson
AU  - McCutcheon,Ian E
AU  - Kurzrock,Razelle
TI  - Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside
SN  - 1527-7755
PY  - 2012///0330
KW  - Adolescent
KW  - Adult
KW  - Angiogenesis Inhibitors
KW  - therapeutic use
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Benzenesulfonates
KW  - Bevacizumab
KW  - Child
KW  - Child, Preschool
KW  - Drug Synergism
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Humans
KW  - Indoles
KW  - Male
KW  - Molecular Targeted Therapy
KW  - methods
KW  - Neurofibromatosis 2
KW  - drug therapy
KW  - Niacinamide
KW  - analogs & derivatives
KW  - Phenylurea Compounds
KW  - Pyridines
KW  - Pyrroles
KW  - Quinazolines
KW  - Sirolimus
KW  - Sorafenib
KW  - Sunitinib
KW  - TOR Serine-Threonine Kinases
KW  - antagonists & inhibitors
KW  - Treatment Outcome
KW  - Valproic Acid
KW  - Vascular Endothelial Growth Factor A
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1200/JCO.2011.38.2614
ER  -